TRUST trial: BAY 86-6150 use in haemophilia with inhibitors and assessment for immunogenicity

摘要

IntroductionThe most serious and challenging complication of haemophilia treatment is development of inhibitors to replacement factors VIII or IX. Innovative therapies currently being explored for patients with haemophilia and inhibitors include BAY 86-6150, a modified recombinant activated factor VII (FVIIa). Immunogenicity remains a substantial barrier in this endeavour.